Want to see TECX full AI Analyst Report?
Top Page
Tectonic Therapeutic
(NASDAQ:TECX)
Select Model
Select Model
Rating:59Neutral
Price Target:
$29.00
▼(-23.10% Downside)
Action:Reiterated
Date:08/19/26
The score is driven primarily by mixed financial performance: a strong, low-debt balance sheet is offset by no revenue and accelerating cash burn. Technical trends provide near-term support as the stock trades well above key moving averages with moderate momentum. Valuation remains weak due to ongoing losses and no dividend, while the completed TX45 Phase 2 enrollment is a notable positive catalyst heading into expected early Q1 2027 data.
Positive Factors
Low leverage and stronger capital base
Very low leverage gives Tectonic financial flexibility while it advances development programs. The substantially stronger equity base and sizeable asset position provide a foundation for research and clinical investment, reducing balance-sheet strain compared with a highly indebted biotechnology model.
Negative Factors
Pre-revenue business model
With no reported revenue, Tectonic lacks commercial cash inflows to support ongoing operations and remains dependent on financing or other capital sources. This makes the company’s durable financial profile highly reliant on successful clinical development and eventual commercialization.
Read all positive and negative factors
Positive Factors
Negative Factors
Low leverage and stronger capital base
Very low leverage gives Tectonic financial flexibility while it advances development programs. The substantially stronger equity base and sizeable asset position provide a foundation for research and clinical investment, reducing balance-sheet strain compared with a highly indebted biotechnology model.
Read all positive factors
Tectonic Therapeutic (TECX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$545.62M
Dividend YieldN/A
Average Volume (3M)213.32K
Price to Earnings (P/E)―
Beta (1Y)1.35
Revenue GrowthN/A
EPS Growth-13.09%
CountryUS
Employees60
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-4.57
Shares Outstanding19,549,366
10 Day Avg. Volume149,024
30 Day Avg. Volume213,319
Financial Highlights & Ratios
PEG Ratio-1.69
Price to Book (P/B)1.52
Price to Sales (P/S)0.00
P/FCF Ratio-6.34
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$78.67Price Target Upside108.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-5.09
Revenue Forecast (FY)N/A
Tectonic Therapeutic Business Overview & Revenue Model
Company Description
Tectonic Therapeutic, Inc. operates as a clinical-stage biotechnology firm dedicated to the identification and progression of biologic therapies, primarily therapeutic proteins and antibodies, that regulate the function of G-protein coupled recept...
How the Company Makes Money
null...
Tectonic Therapeutic Financial Statement Overview
Summary
Income Statement
18
Very Negative
Balance Sheet
74
Positive
Cash Flow
28
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -83.79M | -71.48M | -56.23M | -41.19M | -31.03M | -8.12M |
| Net Income | -85.79M | -74.15M | -57.98M | -42.82M | -32.18M | -8.93M |
Balance Sheet | ||||||
| Total Assets | 237.03M | 261.04M | 152.91M | 39.40M | 47.21M | 32.88M |
| Cash, Cash Equivalents and Short-Term Investments | 227.07M | 253.80M | 141.24M | 28.77M | 35.97M | 28.06M |
| Total Debt | 4.40M | 1.28M | 3.30M | 4.34M | 5.79M | 1.05M |
| Total Liabilities | 13.19M | 9.71M | 12.13M | 124.03M | 92.86M | 47.84M |
| Stockholders Equity | 223.85M | 251.33M | 140.78M | -84.64M | -45.65M | -14.96M |
Cash Flow | ||||||
| Free Cash Flow | -72.45M | -60.29M | -59.24M | -40.96M | -97.47M | -14.58M |
| Operating Cash Flow | -72.14M | -60.08M | -59.08M | -40.68M | -97.21M | -12.45M |
| Investing Cash Flow | -216.00K | -138.00K | -156.00K | -279.00K | -267.00K | -2.12M |
| Financing Cash Flow | 11.93M | 173.35M | 171.71M | 33.75M | 262.00K | 41.42M |
Tectonic Therapeutic Technical Analysis
Negative
37.71
Price Trends
32.08
Negative
31.01
Negative
27.73
Negative
Market Momentum
-1.41
Positive
36.23
Neutral
6.48
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TECX, the sentiment is Negative. The current price of 37.71 is above the 20-day moving average (MA) of 32.01, above the 50-day MA of 32.08, and above the 200-day MA of 27.73, indicating a bearish trend. The MACD of -1.41 indicates Positive momentum. The RSI at 36.23 is Neutral, neither overbought nor oversold. The STOCH value of 6.48 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TECX.
Tectonic Therapeutic Risk Analysis
Tectonic Therapeutic disclosed 78 risk factors in its most recent earnings report. Tectonic Therapeutic reported the most risks in the "Tech & Innovation" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Tectonic Therapeutic Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
59 Neutral | $545.62M | -5.95 | -35.26% | ― | ― | -13.09% | |
58 Neutral | $1.26B | 9.66 | -109.40% | ― | ― | ― | |
52 Neutral | $341.31M | -3.63 | -41.85% | ― | ― | 64.51% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $307.08M | -4.92 | -41.69% | ― | 6280.00% | -212.54% | |
46 Neutral | $42.46M | -1.59 | -74.76% | ― | -100.00% | 44.94% | |
44 Neutral | $247.64M | -4.24 | 72.64% | ― | 51.98% | 17.68% |
* Healthcare Sector Average
TECX
Tectonic Therapeutic
27.21
11.57
73.98%
OMER
Omeros
18.45
14.19
333.10%
ABEO
Abeona Therapeutics
5.59
-0.05
-0.89%
MREO
Mereo Biopharma Group Plc
0.29
-1.48
-83.62%
FHTX
Foghorn Therapeutics
4.20
-0.94
-18.29%
LXEO
Lexeo Therapeutics, Inc.
4.18
-1.28
-23.44%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.